Arbutus Biopharma

Arbutus Biopharma Corp. is a biopharmaceutical company. It engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Arbutus Biopharma advances promising drug candidates and secures financial stability

Arbutus Biopharma showcased progress in its drug development pipeline, particularly with positive Phase IIa trial results for AB-729 and the introduction of AB-343 as a promising oral coronavirus drug candidate. The company's financial stability and strategic focus on upcoming milestones position it well for future growth.

Arbutus Biopharma advances HBV and COVID-19 treatments with strong finances

Arbutus Biopharma is making significant progress in developing treatments for HBV and COVID-19, supported by a strong financial position.
While facing challenges such as FDA clinical holds and trial planning, the company is well-positioned to capitalize on upcoming opportunities.
Strategic focus on clinical advancements, financial stability, and future growth opportunities defines Arbutus Biopharma's outlook for 2023.

Arbutus Biopharma advances Hepatitis B cure development amid financial strength

Arbutus Biopharma is progressing well in its quest for a functional cure for chronic Hepatitis B, supported by a strong pipeline and financial stability.
The company faces challenges in navigating development hurdles and competition but has opportunities to lead in innovative therapies for HBV and COVID-19.
By focusing on key milestones, strategic trial designs, and effective resource management, Arbutus aims to drive growth and success in the biopharmaceutical sector.

Arbutus Biopharma focuses on HBV cure amid leadership transition

Arbutus Biopharma's strategic focus on developing a functional cure for chronic HBV and maintaining financial stability through 2026 positions the company for future growth.
While workforce reduction and legal challenges present hurdles, the company's pipeline progress and leadership transition signal resilience and adaptability.
Opportunities in pipeline expansion, partnerships, and clinical trial advancements underscore Arbutus Biopharma's potential for long-term success in the biopharmaceutical industry.

Arbutus Biopharma focuses on HBV cure, extends cash runway

Arbutus Biopharma's Q4 2023 earnings call highlighted a strategic focus on HBV and extending cash runway. Progress in clinical trials and ongoing litigation efforts against key players. Anticipating reduced cash burn in 2024 for financial sustainability.

Arbutus Biopharma reports strong financials and progresses HBV treatment pipeline

Arbutus Biopharma showcased a strong financial position and positive results in Phase 1a study of AB-836.
The company's focus on developing a functional cure for chronic HBV and advancing pipeline assets demonstrates commitment to innovation.
While facing questions on dosing strategies and trial designs, Arbutus sees opportunities in upcoming data releases and advancing clinical studies.

Arbutus Biopharma reports promising HBV trial results and financial strength

Arbutus Biopharma demonstrates positive trial results and financial stability, positioning the company well for future growth and innovation in HBV treatment
Challenges in trial design, data interpretation, and legal proceedings require careful navigation to capitalize on opportunities for advancement
Opportunities lie in further data reporting, biomarker exploration, and potential partnerships to drive progress towards a functional cure for chronic hepatitis B

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Arbutus expects to have data readouts from three phase 2 triple combination studies using AB-729 for Hepatitis B in the 2nd half of 2022.

Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest

Arbutus Biopharma Corporation (ABUS) CEO William Collier on Q4 2021 Results - Earnings Call Transcript

Anticipate reporting data from four clinical trials in chronically infected HBV patients in 2022

Arbutus Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update

Moderna

Shares of Arbutus Biopharma Corp. ABUS, +7.21% gained 11.0% in premarket trading on Monday after the company said it is suing Moderna Inc. MRNA, +1.70% for infringing on several patents that relate to Moderna's COVID-19 vaccine. Arbutus filed the lawsuit with Genevant Sciences Corp., a privately held company.

Arbutus, Genevant sue Moderna, citing patent infringement

Arbutus Biopharma Corp said on Monday it had filed a lawsuit against Moderna Inc seeking damages for infringement of patents related to its COVID-19 vaccine.

Arbutus files patent infringement lawsuit against Moderna

WARMINSTER, Pa., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, and Genevant Sciences today filed a lawsuit in the U.S. District Court for the District of Delaware against Moderna, Inc. (Nasdaq: MRNA) and a Moderna affiliate seeking damages for infringement of U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of MRNA-1273, Moderna's vaccine for COVID-19. The patents relate to nucleic acid-lipid particles and lipid vesicles, as well as compositions and methods for their use. The filed complaint is available on the Arbutus website.

Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Moderna

VANCOUVER, British Columbia and CAMBRIDGE, Mass. and BASEL, Switzerland, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company, and Arbutus Biopharma Corporation (Nasdaq: ABUS) today filed a lawsuit in the U.S. District Court for the District of Delaware against Moderna, Inc. (Nasdaq: MRNA) and an affiliate seeking damages for infringement of U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of mRNA-1273, Moderna's vaccine for COVID-19. The patents relate to nucleic acid-lipid particles and lipid vesicles, as well as compositions and methods for their use. The filed complaint is available at https://investor.roivant.com/news-events/events.

Genevant Sciences and Arbutus Biopharma File Patent Infringement Lawsuit Against Moderna

CTI BioPharma

IronNet

Tellurian

Penny stocks to buy for under $5 that have unusual options activity right now. The post 4 Penny Stocks To Buy For Under $5 With Unusual Options Activity appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Buy For Under $5 With Unusual Options Activity

WARMINSTER, Pa., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its fourth quarter and year end 2021 financial results and corporate update for Thursday, March 3, 2022. The schedule for the press release and conference call/webcast are as follows:

Arbutus to Report Fourth Quarter and Year End 2021 Financial Results and Provide Corporate Update

The company could have great prospects if its hepatitis B virus therapy is successful in clinical testing.

What's the Outlook for Arbutus Biopharma?

Multiple AB-729 and AB-836 HBV clinical data readouts anticipated to guide future clinical development and regulatory strategies

Arbutus Announces 2022 Corporate Objectives and Provides Financial Update

WARMINSTER, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of assets with different modes of action to provide a cure for people with chronic hepatitis B virus infection and to treat coronaviruses (including COVID-19), today announced that the Company will participate in a virtual fireside chat at the H.C. Wainwright Bioconnect Virtual Conference taking place January 10 - 13, 2022.

Arbutus to Participate at H.C. Wainwright Bioconnect Virtual Conference

ROIV has moved up 88% in December in reaction to a patent dispute between Moderna and Arbutus falling in favor of Arbutus. The patent is licensed to a private company called Genevant. ROIV owns an effective 88% stake through direct ownership and its stake in ABUS.

Roivant Sciences Nearly Doubles Since Moderna Patent Ruling, Buy Arbutus

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company with research specialization in chronic hepatitis B virus (HBV). In December 2021, ABUS reported its victory in the patent dispute over Moderna, involving its licensed four-lipid nanoparticles delivery system.

Arbutus Biopharma: How Will Patent Win Impact Stock Outlook?

Alzamend Neuro

Katapult Holdings

Progenity

5 penny stocks analysts say are a buy right now with hefty price targets. The post Penny Stocks To Buy According To 5 Analysts With 55%-246% Targets appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy According To 5 Analysts With 55%-246% Targets

MENDHAM, N.J. and WARMINSTER, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. (“Antios”) and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the first patient has been dosed in a triple combination treatment in patients with chronic hepatitis B virus (HBV) infection. A single cohort in the ongoing Antios Phase 2a SAVE-1 (Sustained Anti-Viral Efficacy) clinical trial will evaluate a triple combination of Antios' proprietary active site polymerase inhibitor nucleotide (ASPIN), ATI-2173, Arbutus' proprietary GalNAc delivered RNAi therapeutic, AB-729, and tenofovir disoproxil fumarate (TDF), a nucleotide reverse transcriptase inhibitor.

Antios Therapeutics and Arbutus Biopharma Announce First Patient Dosed in Phase 2a Combination Trial of ATI-2173, AB-729 and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B Virus Infection

The stock price of Arbutus Biopharma Corp (NASDAQ: ABUS) increased by over 3% during intraday trading. This is why it happened.

Arbutus Biopharma Stock (ABUS): Why The Price Increased Today

Arbutus Biopharma Corp (NASDAQ: ABUS) shares are trading higher after the company announced it received a $40M upfront payment from Qilu to commercialize AB-729 in Asia. William Collier, President and Chief Executive Officer of Arbutus Biopharma, commented, "Qilu is an ideal partner for our AB-729 RNAi therapeutic given their extensive development, regulatory and commercialization capabilities in China.

Why Arbutus Biopharma Shares Are Rising

Qilu Pharmaceutical, one of the leading pharmaceutical companies in China, becomes strategic partner to provide development, manufacturing and commercialization expertise for the mainland China, Hong Kong, Macau and Taiwan markets

Arbutus and Qilu Pharmaceutical Enter into an Exclusive Licensing Agreement and Strategic Partnership to Develop and Commercialize AB-729 in mainland China, Hong Kong, Macau and Taiwan

Aprea Therapeutics

Remark Hlds

Meten Holding Group Ltd.

Got $5 to spend on penny stocks? Take a look at these four for your watchlist The post Got $5 to Spend on Penny Stocks?

Got $5 to Spend on Penny Stocks? Check These 4 Out

Ensysce Biosciences

Genius Brands

Vyne Therapeutics

Are these Reddit penny stocks on your watchlist right now? The post 4 Penny Stocks That Are Trending on Reddit Right Now and Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks That Are Trending on Reddit Right Now and Why

Biofrontera

Idera Pharmaceuticals

ReWalk Robotics

SPI Energy

Analysts are bullish on these penny stocks in 2021. Should you be?

5 Penny Stocks To Buy According To Analysts & Targets Up To 341%

The stock price of Arbutus Biopharma Corp (NASDAQ: ABUS) increased by over 10% during intraday trading today. This is why it happened.

Arbutus Biopharma (ABUS) Stock: Why The Price Jumped Today

Arbutus Biopharma Corporation (NASDAQ: ABUS) has identified several molecules that inhibit the SARS-CoV-2 nsp5 main protease (Mpro), a validated target for treating COVID-19 and potential future coronavirus outbreaks.  In April 2021, Arbutus, X-Chem Inc, and Proteros biostructures GmbH entered a discovery research and license agreement of novel inhibitors targeting the SARS-CoV-2 nsp5 main protease.

Arbutus Biopharma Shares Jump After Achieving First Milestone Under COVID-19 Pact

﻿Screening identifies several unique compound series that inhibit the SARS-CoV-2 nsp5 main protease, a validated target for the treatment of COVID-19 and potential future coronavirus outbreaks

News for Arbutus Biopharma Stock (ABUS)